جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

9 مُخرَج نتائج البحث عن «Pulmonary fibrosis»

مقالمفتوح (مستودع)20246استشهاد· Semantic Scholar

One-pot synthesis and pharmacological evaluation of new quinoline/pyrimido-diazepines as pulmonary antifibrotic agents

Future Medicinal Chemistry · مجلد 16 (21) · 2211-2230

Aim: Pulmonary fibrosis is a life threating disease which requires an immediate treatment and due to the limited medications, this study focused on synthesizing a series of quinoline-based pyrimidodiazepines 4a–f as a novel antifibrotic hit.Materials & methods: The target compounds were synthesized via a one-pot reaction then investigated in a rat model of lung fibrosis induced by bleomycin (BLM).Results: Results revealed significant attenuation of the tested pro-inflammatory cytokines, fibrotic genes and apoptotic markers; however, Bcl-2 was upregulated, indicating a protective effect against fibrosis. Moreover, the molecular docking studies highlighted promising interactions between compounds 4b and 4c and specific amino acids within the protein pockets of caspase-3 (ARG341 and THR177), malondialdehyde (LYS195, LYS118 and ARG188) and TNF-α (SER99 and NME102).Conclusion: Compounds 4b and 4c emerge as promising candidates for further preclinical investigation as pulmonary antifibrotic agents.

pulmonary fibrosisantifibrotic agentsquinoline derivativesone-pot synthesis
مقالمفتوح (مستودع)20231استشهاد· Semantic Scholar

Interferon-λ3 rs12979860 can regulate inflammatory cytokines production in pulmonary fibrosis

Saudi Pharmaceutical Journal · مجلد 31 (11) · 101816-101816

Pulmonary fibrosis (PF) is the last phase of interstitial lung diseases (ILDs), which are a collection of pulmonary illnesses marked by parenchymal remodeling and scarring. Treatment can only halt the functional decline of the lung, raising the necessity of identifying the basic processes implicated in lung fibrogenesis. The Interferon lambda-3 (IFNL3) gene variant, rs12979860, was determined to be related to an elevated risk of fibrosis in different organs, but the mechanism through which it mediates fibrogenesis is not clear. In the current research, we aim to figure out some of the mechanistic pathways by which IFN-λ3 mediates ILDs. 100 healthy controls and 74 ILD patients were genotyped for IFNL3 rs12979860. Then the mRNA expression of IFNL3 and some other proinflammatory mediators was examined according to genotype in the peripheral blood mononuclear cells (PBMCs) of ILDs patients. The IFNL3 rs12979860 genotype distribution of healthy individuals and ILDs patients was shown to be in Hardy-Weinberg equilibrium (HWE) with a minor allele frequency (MAF) of 0.293 and 0.326, respectively. Furthermore, the CC genotype was demonstrated to be linked to enhanced IFNL3 expression. Also, the CC genotype was linked to an increase in the mRNA expression of TLR4 (P =0.03) and the inflammatory cytokines IL-1β and TNF-α (P =0.01 and 0.04, respectively) and had no effect on the NF-kB level (P =0.3). From these results, we can deduce that IFN-λ3 may mediate tissue fibrosis via increasing the expression of IFN-λ3 itself and other proinflammatory mediators. This stimulates a self-sustaining loop mechanism which includes a reciprocal production of IFN-λ3, TLR4, IL-1β, and TNF-α leading to persistent inflammation and fibrosis.

IL28Bpulmonary fibrosisinterstitial lung diseasegenetic polymorphism
مراجعةوصول مفتوح202137استشهاد· Semantic Scholar

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health · مجلد 14 (8) · 1075-1086

The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009. This patent review summarizes the remdesivir based inventions to treat/prevent COVID-19 and other disorders from 2009 to May 16, 2021, emphasizing the patents related to medical and pharmaceutical sciences. The primary patents/patent applications of remdesivir are related to its compositions, new combinations with other therapeutic agents, delivery systems, and new indications. The inventive combinations have displayed synergistic effects against COVID-19, whereas the delivery systems/compositions have improved patient compliance. The inventions related to new indications of remdesivir to treat Ebola, hepatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and cardiovascular complications enhance its therapeutic area. Many new innovative combinations and delivery systems of remdesivir are anticipated to provide better treatment for COVID-19.

remdesivirCOVID-19 pandemicpatentscombination therapy
مراجعةوصول مفتوح202113استشهاد· Semantic Scholar

Current Overview on Therapeutic Potential of Vitamin D in Inflammatory Lung Diseases

Biomedicines · مجلد 9 (12) · 1843-1843

Inflammatory lung disorders (ILDs) are one of the world's major reasons for fatalities and sickness, impacting millions of individuals of all ages and constituting a severe and pervasive health hazard. Asthma, lung cancer, bronchiectasis, pulmonary fibrosis acute respiratory distress syndrome, and COPD all include inflammation as a significant component. Microbe invasions, as well as the damage and even death of host cells, can cause and sustain inflammation. To counteract the negative consequences of irritants, the airways are equipped with cellular and host defense immunological systems that block the cellular entrance of these irritants or eliminate them from airway regions by triggering the immune system. Failure to activate the host defense system will trigger chronic inflammatory cataracts, leading to permanent lung damage. This damage makes the lungs more susceptible to various respiratory diseases. There are certain restrictions of the available therapy for lung illnesses. Vitamins are nutritional molecules that are required for optimal health but are not produced by the human body. Cholecalciferol (Vitamin D) is classified as a vitamin, although it is a hormone. Vitamin D is thought to perform a function in bone and calcium homeostasis. Recent research has found that vitamin D can perform a variety of cellular processes, including cellular proliferation; differentiation; wound repair; healing; and regulatory systems, such as the immune response, immunological, and inflammation. The actions of vitamin D on inflammatory cells are dissected in this review, as well as their clinical significance in respiratory illnesses.

vitamin Dvitamin D3inflammatory lung diseaseairway inflammation
مقالوصول مفتوح202113استشهاد· Semantic Scholar

Leflunomide Induces Dose-Dependent Lung Injury in Mice via Stimulating Vimentin and NLRP3 Inflammasome Production

Frontiers in Pharmacology · مجلد 12 · 631216-631216

Recently, the therapeutic importance of the anti-rheumatic drug, leflunomide, has been increased after the involvement of leflunomide in treating other autoimmune diseases and its promising role in retarding human malignancies. Few studies have focused on the safety in human or animals without clear outlining of the pathologic features on target organs. One clinical study related leflunomide with significant pulmonary complications in predisposed individuals. The current study examined the dose-dependent lung injury produced by leflunomide in healthy mice. Albino mice were allocated into four different groups. Group (1): Vehicle control group, Group (2-4): mice received leflunomide (2.5, 5 or 10 mg/kg), respectively, for 8 weeks and then lungs were dissected from the mice for histopathological examination and fibrosis evaluation (Masson's trichrome staining and α-smooth muscle actin immunohistochemistry). Enzyme linked immunosorbent assay was used to assess the vimentin and other inflammatory factors in the lung homogenate whereas Western blot analysis was employed to assess α-smooth muscle actin, vimentin and collagen 1. Results indicated that leflunomide induced dose-dependent pulmonary injury and the high dose and increased the vimentin, inflammatory markers (NLRP3 and interlukin-1β). Histologic examination showed distorted architecture, marked inflammatory cells infiltrate and increase collagen content. The findings were supported by Western blotting and the immunohistochemical study which showed greater pulmonary α-smooth muscle actin and vimentin content. In conclusion, the current results highlighted that leflunomide produced dose-dependent pulmonary toxicities that requires further investigation of the nature of injury.

leflunomidepulmonary toxicitylung injuryvimentin
مقالوصول مغلق202018استشهاد

Glycyrrhizic acid ameliorates sodium nitrite-induced lung and salivary gland toxicity: Impact on oxidative stress, inflammation and fibrosis

Human & Experimental Toxicology · مجلد 40 (4) · 707-721

Despite wide application of sodium nitrite (SN) as food additive, it exhibits considerable side effects on various body organs at high dose or chronic exposure. The aim of this study was to test whether Glycyrrhizic acid (GA) could ameliorate SN-induced toxicity in lung and submandibular salivary gland (SMG). A sample size of 30 adult male albino rats was randomly allocated into 3 groups. Group 1 served as control group. Rats were treated orally with 80 mg/kg of SN in group 2 or SN preceded by (15 mg/kg) GA in group 3. Lung & SMG tissues were used for oxidative stress assessment, examination of histopathological changes, fibrosis (MTC, TGF-β and α-SMA) and inflammation (TNF-α, IL-1β and CD-68). Concurrent administration of GA ameliorated pulmonary and salivary SN-induced toxicity via restoring the antioxidant defense mechanisms with reduction of MDA levels. GA reduced the key regulators of fibrosis TGF-β and α-SMA and collagen deposition. In addition to reduction of inflammatory cytokine (TNF-α, IL-1β) and macrophages recruitments, GA amended both pulmonary and salivary morphological changes. The present study proposed GA as a promising natural herb with antioxidant, anti-inflammatory and antifibrotic effects against pulmonary and salivary SN-induced toxicity.

glycyrrhizinsodium nitritefood additive toxicitypulmonary toxicity
مقالمفتوح (مستودع)2016

Chronic Cough: Common Causes in Sudanese Young Adults

Journal of Lung Pulmonary & Respiratory Research · مجلد 3 (3)

Background: Chronic cough has been reported to be the fifth most common complaint seen by primary care physicians.Diseases causing chronic cough include asthma, eosinophilic bronchitis, GERD (Gastro esophageal Reflux Disease), PNDS (Post Nasal Drip Syndrome) or rhinosinusitis, chronic obstructive pulmonary disease, pulmonary fibrosis, lung tumors, tuberculosis and bronchiectasis.In some patients, no cause is identified, leading to the diagnosis of idiopathic cough or UCC (Unexplained Chronic Cough).Chronic cough is associated with deterioration in patients' quality of life and the health-related dysfunction is most likely psychosocial.Methods: This study was carried out to assess incidence of specialist chest physician visits attributable to chronic cough and to characterize patients and their underlying causes for chronic cough.One hundred and fifty subjects, who presented with chronic cough as their main complaint to our clinic setting in Khartoum North, were assessed clinically and investigated (Guided by the ACCP Approach).The specific causes were confirmed by appropriate investigations, as well as response to specific therapy.If rhinosinusitis was suspected, patients were then referred to otolaryngologist for an ENT workup.Results: The frequency of chronic cough among patients was 13%, it was more frequent in females than in males, and there was increased chronic cough incidence with advancing age.Out of the 150 patients; 53 patients (35%) had chronic rhino-sinusitis; 43 patients (29%) had asthma and 30 patients (20%) had GERD.Other causes like tuberculosis and smoking constituted the remaining 16% of the patients.Conclusion: Chronic cough remains a common benign disorder with rhinosinusitis as its principal cause, followed by asthma and gastro esophageal reflux disease.The cause of chronic cough could be frequently outside the lower respiratory tract.Cough duration and the age of patient are important in the diagnostic workup.

chronic coughunexplained chronic coughchronic rhinosinusitisasthma